US FDA Approves Moderna’s Skin Cancer Therapy
On, February, 22, 2023, Moderna Inc. said that US regulators have given its experimental personalised mRNA skin cancer vaccine and Merck & Co.’s drug Keytruda the designation of breakthrough therapies as an additional treatment for high-risk patients. After the market closed Moderna shares rose 2.5% to $164. Based on data from a mid-stage drug study […]
Continue Reading